Randomization is a common technique used in clinical trials to eliminate potential bias and confounders in a patient population. Equal allocation to treatment groups is the standard due to its high efficiency in many cases. However, in certain scenarios, unequal allocation can improve efficiency. In superiority trials with more than two groups, the optimal randomization is not always a balanced randomization. Non-inferiority trials are clinical trials designed to establish a new treatment that is not much worse than the current treatment or control. In non-inferiority trials, additive margin with equal variance is the only instance with balanced randomization. A tool for sample size calculation for non-inferiority trials with additive or multiplicative margin with normal, binomial or Poisson distribution is available at http://www.statlab.wisc.edu/shiny/SSNI/.
INTRODUCTION
Randomization remains a gold standard method in clinical trial methodology to eliminate potential bias and confounders. Randomization eliminates a systematic difference between subjects in treatment groups inducing approximate balance with respect to covariates, both observed and unobserved. Equal allocation to treatments groups is the standard due to its high efficiency in many cases. Statistical efficiencies are directly related to statistical power. Thus, increasing statistical efficiencies improves the likelihood of correctly rejecting the null hypothesis when the alternative is true.
However, there is a huge controversy over the ethics of randomization. The introduction of response-adaptive treatment brings about the idea of "play the winner" rule 1 . Besides the idea of adjusting the treatment allocation depending on the response of the drug, people also tend to question the use of imbalance treatment allocation. However, there is a growing trend in trials with imbalance treatment allocation 2 . Imbalance trial seems to be a favorable trial due to several constraints such as limitation of available resources, increase chances of attaining required sample size and testing the side effects of a new treatment/drug.
In certain trials, limitation of resources tend to hinder the success of a trial. Thus, investigators tend to reduce the patient allocation in the scarce group to overcome this issue. For instance, in the CPORT trial, if the availability of on-site cardiac surgery is a scarce resource, then the study could randomize more patients to the group of off-site cardiac surgery to overcome this issue. However, this was not the real reason behind the choice of 3:1 randomization in the CPORT study. Patients were randomized 3:1 to provide sufficient training to surgeons. On the other hand, the cost can also contribute to the imbalance in a trial 2 . Imbalance allocation of patients might be beneficial to reduce the overall cost of a trial. Patients tend to be frustrated with equal allocation trials of a deadly disease due to the low chances of getting the new treatment 3 . Thus, imbalance trials tend to attract more patients due to a higher tendency of getting a new treatment. However, sometimes an imbalance trial could reduce the statistical power and increase the sample size required 2 . Researchers have to be careful in designing trials to prevent failure in answering the primary questions in the trial. Even though early phase trials are designed to study the efficacy of dosage of new treatment, these trials are conducted in a small sample and they fail to capture the complete effect of a treatment. Thus, imbalance trials favoring the new treatment might be helpful to further analyze side effects of dosage in the new treatment.
After briefly looking at optimal randomization ratio for multiple doses against control in superiority trial with equal and unequal variance, we provide a quick introduction to non-inferiority trial. Then, we move on to the optimal allocation derivation in a non-inferiority trial with equal and unequal variance and additive and multiplicative non-inferiority margin. We also derived the sample size and number of events required in a non-inferiority trial with additive or multiplicative non-inferiority margin before moving on to illustrate the Cardiovascular Patient Outcomes Research Team (CPORT) study where optimal allocation could have optimized the trial.
THE "ALL-DOSES-AGAINST-CONTROL" CASE
Dunnett's paper on A Multiple Comparison Procedure for Comparing Several Treatments with a Control illustrates the low efficiency of assigning all treatments equally for multiple treatments versus control, however, the paper did not provide a closedform solution 4 . The derivation below provides a closed form solution for all doses against control case where the experimental group is compared to the control alone.
Equal variance
Consider a superiority trial in which multiple doses are compared to the control dose with total sample size of and variance 2 . There are a total of groups, where group 1 is the control dose and the other − 1 groups are the experimental doses, and we want to compare the experimental groups to the control but not to each other.
The sample size allocated in the control group is and every other group is allocated
. In order to compute the optimal , we minimize the total variance below with respect to , (0 < < 1).
The asymptotic relative efficiency (ARE) of the optimal allocation (A1) relative to equal allocation (A2) is The optimal solution for the 1 , ..., −1 is
Unequal variance
The asymptotic relative efficiency of the optimal allocation (A1) relative to equal allocation (A2) is
EFFICIENCY VS. RANDOMIZATION RATIO IN NON-INFERIORITY TRIALS

Non-inferiority trial
Non-inferiority trials are clinical trials designed to establish a new treatment that is not that much worse than the current treatment or control 5 . Thus, a new treatment can be favorable even if it is slightly inferior or worse off than the current treatment. Unlike equivalence trial, non-inferiority trial does allow the possibility of the new treatment being better off than the standard treatment 6 . The new treatment is believed to offer ancillary benefit in terms of side effects, safety or even price.
A margin is introduced to allow a small loss in efficacy in the new treatment compared to the control treatment. This margin serves as a maximum acceptable threshold 7 . Researchers believe the threshold should be determined in advance even though it is subjective 8 . Factors such as historical data and physician's experience play a vital role in the decision of setting a margin for a non-inferiority trial. The selection of margin scale used (difference in means of two groups, ratios of means, etc.) is less commonly stated but it is important for computing sample sizes 9 . Let's denote Δ > 0 for additive margin and Δ > 1 for multiplicative margin. The corresponding non-inferiority trial hypotheses for additive margin to test the difference in means are
where is the mean of the control group and is the mean of the experimental group. On the other hand, the corresponding non-inferiority trial hypotheses for multiplicative margin to test the differences in means are
where is the mean of the control group and is the mean of the experimental group. The higher mean is considered favorable. SPORTIF III trial was a non-inferiority trial conducted to compare new treatment ximelagatran to the active control warfarin for the prevention of ischemic strokes in patients with atrial fibrillation 10 . Figure 1 shows seven different possible hypothetical outcomes from SPORTIF III with Δ = 2%. The top three cases, illustrate situations where the new treatment is non-inferior to the current treatment. The fourth and fifth cases demonstrate possibilities where no proper conclusion can be drawn. In the sixth case, the new treatment suggests superiority over the control treatment. The last outcome is a situation in which the new treatment is inferior to the current treatment.
FIGURE 1
Hypothetical outcomes from the SPORTIF III trial with point estimates and 95% two-sided confidence intervals.
Imbalance in non-inferiority trial: equal variance
It has been shown previously that equal allocation may not be optimal in non-inferiority trials 7, 11 . The optimal allocation for different scenarios are computed below. The variance is equal for the both the treatment and control groups and denoted by 2 .
Optimal allocation for additive
In this case, the optimal randomization ratio is 1:1 since ( ) = ( ) .
Optimal allocation for multiplicative
The optimal sample size allocated in the control group is ℎ and every other group is allocated (1-ℎ) . In order to compute the optimal ℎ, we minimize the variance below with respect to ℎ, (0 < ℎ < 1).
Imbalance in non-inferiority trial: unequal variance
The variance in the treatment groups are not equal, for example with binomial or Poisson outcomes. The variance is denoted by 2 = ( ), ( ) is the variance of treatment and it is a function of .
Optimal allocation for additive
Optimal allocation for multiplicative
The general case for generalized linear models
The derivation for binomial and poisson null hypothesis are illustrated below. In the binomial case, consider and as the probability of success for control and treatment group. Meanwhile, in the Poisson group consider and as the mean of control and treatment group respectively.
Binomial: additive hypothesis
Binomial: multiplicative hypothesis
Poisson: additive hypothesis
Poisson: multiplicative hypothesis
Survival analysis
In most clinical trials, the power of the study is highly dependent on the occurrence of events and sample size in the study (N).
The optimal sample size is sufficient for the success of a trial, a small sample size is usually not powerful to reject the null and a large sample size is usually a waste of resource. We have computed the number of events required in the section below for non-inferiority trial with an additive hypothesis and a multiplicative hypothesis. Some of the derivations were adopted from Machin et al. (2009) chapter on comparing survival curves 12 . We denote and as the survival proportions for the control and treatment group respectively at some chosen time-point.
Additive hypothesis: Log Rank Test
Let's assume patients enter the trial with randomization ratio of 1 ∶ (control : treatment). The Hazard ratio is assumed to be inversely related to the mean ( = +Δ ). The number of events required in the control group and treatment group are 
Multiplicative hypothesis: Log Rank Test
Let's assume patients enter the trial with randomization ratio of 1 ∶ (control : treatment). The Hazard ratio is assumed to be inversely related to the mean ( = Δ). The number of events required in the control group and treatment group are
The sample size required in the control group and treatment group are
EXAMPLE: CPORT
The Cardiovascular Patient Outcomes Research Team (CPORT) study provides a motivating example for the current work. In the CPORT study, physicians were interested in comparing the performance of percutaneous coronary intervention (PCI) at hospitals with vs. hospitals without on-site cardiac surgery 13 . PCI is usually restricted to hospitals with on-site cardiac surgery which limits patient's availability to receive the treatment. Based on previous studies, the six weeks (all-cause) rate of mortality was estimated to be 0.8%. The six weeks rate of mortality of the experimental group (performance of PCI without on-site surgery) is set at 1.2% and would be considered non-inferior if the rate of mortality remains below 1.2%. The other primary outcome was the rate of nine months major adverse cardiac events which were estimated to be 12% with a noninferiority margin of 1.8%.
CPORT was a multi-center randomized trial with 18,867 patients who were randomized at 3:1 to undergo PCI with 14,149 patients undergoing PCI at a hospital without on-site cardiac surgery and 4,718 patients undergoing PCI at hospitals with onsite cardiac surgery. Both the margins used in the primary outcome are additive. The six week mortality rate observed was 0.9% at hospitals without on-site surgery and 1% vice versa. The 95% CI for the difference in six-week mortality rate was -0.31 to 0.23 with a p-value of 0.004 for non-inferiority. However, the nine-month rates of major adverse cardiac events were higher at a hospital without on-site cardiac surgery (12.1% and 11.2%). The 95% CI for the difference in the nine-month rate of major adverse events was 0.04 to 1.80 with a p-value of 0.05 for non-inferiority. The results suggest that PCI performed at hospitals without on-site cardiac surgery was non-inferior to PCI performed at hospitals with on-site cardiac surgery with respect to mortality at six weeks and major adverse cardiac events at nine months.
However, the 3:1 randomization was not optimized statistically. The optimal randomization ratio is 1.22:1 which is illustrated in Figure 2 using relative efficiency curve. The computation of optimal allocation for different randomization ratio is illustrtaed in Figure 2 and Table 1 
FIGURE 2
Relative efficiency plot of CPORT trial versus randomization ratio of performing PCI at hospitals with no on-site cardiac surgery. The optimal randomization ratio is 1.22:1.
DISCUSSION
We have developed optimal allocation for superiority trial with multiple drugs versus control and computed the relative efficiency compared to a balanced allocation. The optimal allocation is usually unbalanced in a superiority trial with multiple drugs versus control. Even with superiority trials comparing two binomial endpoints, the optimal randomization is not 1:1 because the power calculations use the variance of the difference in proportions under the alternative 14 . In non-inferiority trials, additive margin with equal variance is the only instance with balanced randomization. With multiplicative margins, 1:1 randomization is less effective because we are estimating a weighted sum and even with additive margins in non-inferiority trials, subject's variance differs under 0 with binary outcomes (binomial).
As we demonstrated in the earlier sections, it is sometimes optimal to implement an unequal allocation. In designing clinical trials, the ethical concerns intertwine with proper scientific judgment. Researchers have to be careful and wise in planning a trial to prevent failure in achieving the primary outcome.
An application for sample size calculator in non-inferiority trial with randomization ratio and relative efficiency to balanced randomization is available at http://www.statlab.wisc.edu/shiny/SSNI/. The sample size calculator computes sample sizes for multiplicative or additive margin with normal, binomial or poisson distribution. The application also reveals other randomization ratio with their relative efficiency compared to the optimal allocation.
FIGURE 3
The tool for sample size calculation for non-inferiority trial with additive or multiplicative margin with normal, binomial or poisson distribution. 
Relative Efficiency
FIGURE 4
The asymptotic relative efficiency of optimal allocation relative to equal allocation in multiple treatments versus control in with a equal variance.
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SUPPORTING INFORMATION
The following supporting information is available as part of the online article: Figure 4 shows the relative efficiency of optimal allocation relative to equal allocation in superiority trial for different number of treatments (control included) in section 1.1. The relative efficiency is always > 1 suggesting optimal allocation is not equal allocation. As number of drugs increases, the relative efficiency of optimal allocation relative to equal allocation also increases. 
FIGURE 5
The asymptotic relative efficiency of optimal allocation relative to equal allocation in non-inferiority trial with multiplicative & additive Δ and equal & unequal variance, ( = 2, = 3) with different Δ's. Figure 5 shows the relative efficiency of optimal allocation relative to equal allocation in non-inferiority trial. Each line represents different non-inferiority trial design. The red and green line represents additive Δ with equal variance and unequal variance respectively while the blue and purple represents multiplicative Δ with equal variance and unequal variance respectively. For additive Δ, the line is shown for 0 < Δ ≤ 0.5 and for multiplicative Δ, the line is shown for 1 < Δ ≤ 1.5 . For unequal variance, the is set to = 2 and = 3. The improvement of efficiency in the non-inferiority trial with unequal variance case can be quite large.
